ImageneBio (NASDAQ:IMA) Stock Price Up 1.8% – Should You Buy?

ImageneBio, Inc. (NASDAQ:IMA)’s stock price was up 1.8% during mid-day trading on Tuesday . The company traded as high as $5.74 and last traded at $5.68. 7,345 shares were traded during trading, a decline of 26% from the average session volume of 9,902 shares. The stock had previously closed at $5.58.

Wall Street Analysts Forecast Growth

IMA has been the topic of several research analyst reports. Wedbush reissued an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. Wall Street Zen lowered ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $30.00.

ImageneBio Price Performance

The company has a market capitalization of $64.69 million, a PE ratio of -1.24 and a beta of 0.76. The business has a 50-day moving average of $5.79 and a 200 day moving average of $5.88.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.27. As a group, research analysts anticipate that ImageneBio, Inc. will post -3.07 EPS for the current year.

Institutional Investors Weigh In On ImageneBio

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in ImageneBio by 13.5% during the fourth quarter. Geode Capital Management LLC now owns 54,146 shares of the company’s stock valued at $374,000 after purchasing an additional 6,458 shares in the last quarter. Barclays PLC increased its holdings in shares of ImageneBio by 170.8% in the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after buying an additional 6,810 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of ImageneBio in the 4th quarter worth about $76,000. Millennium Management LLC bought a new stake in shares of ImageneBio in the 4th quarter worth about $79,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of ImageneBio during the 3rd quarter valued at about $104,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.